A Study of Human Cytomegalovirus (HCMV) Vaccine SPYVLP01 With and Without Adjuvants

NCT06145178 | Completed Phase 1

• 1 other identifier: SPYVAC01
• Study Type: interventional
• Target: 120
• Locations: 1 country
• Sites: 2

Brief Summary

The main purpose of the study is to evaluate the safety and immunogenicity of SPYVLP01 in two different doses with and without adjuvants in healthy adults aged 18-50 years old.

Conditions

Cytomegalovirus Infections

Outcome Measures

Primary Outcomes (2)

• To assess the safety profile of the vaccine with and without adjuvants

  The specific endpoints for safety will be actively and passively collected data on Adverse Events (AEs). The following parameters will be assessed: * Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following each vaccination * Occurrence of unsolicited AEs for 28 days following each vaccination * Change from baseline for safety laboratory measures for 28 days following each vaccination * Occurrence of Serious Adverse Events (SAEs) during the whole study duration * Occurrence of Adverse events of special interest (AESIs) during the whole study duration

  ongoing for 12 months

• To assess the reactogenicity profile of the vaccine with and without adjuvants

  The specific endpoints for reactogenicity will be actively and passively collected data on AEs. The following parameters will be assessed: * Occurrence of solicited local and systemic reactogenicity signs and symptoms for 7 days following each vaccination * Occurrence of unsolicited AEs for 28 days following each vaccination * Change from baseline for safety laboratory measures for 28 days following each vaccination * Occurrence of SAEs during the whole study duration * Occurrence of AESIs during the whole study Duration

  ongoing for 12 months

Secondary Outcomes (1)

• To investigate the pentamer specific binding antibodies and neutralizing antibodies solicited by each arm in seropositive and seronegative healthy male and female adult volunteers

  ongoing for 12 months

Study Arms (6)

Group 1

EXPERIMENTAL

Low dose SPYVLP01 alone

Biological: SPYVAC01

Group 2

EXPERIMENTAL

High dose SPYVLP01 alone

Biological: SPYVAC01

Group 3

EXPERIMENTAL

Low dose + Alhydrogel

Biological: SPYVAC01

Group 4

EXPERIMENTAL

High dose + Alhydrogel

Biological: SPYVAC01

Group 5

EXPERIMENTAL

Low dose + Matrix-M

Biological: SPYVAC01

Group 6

EXPERIMENTAL

High dose + Matrix-M

Biological: SPYVAC01

Interventions

SPYVAC01 BIOLOGICAL

Novel vaccine SPYVLP01

Group 1; Group 2; Group 3; Group 4; Group 5; Group 6

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Healthy male and female adult volunteers aged 18 to 50 years with a body mass index (BMI) of 19 to 32 kg/m2
• Written informed consent before initiation of any study-specific procedures
• Willing and able to understand and comply with study requirements
• Women of childbearing potential must have a negative pregnancy test at screening and prior dose 1 of vaccine.
• Women of childbearing potential must agree to practice a highly effective form of contraception continuously until 90 days after receiving the last immunization.
• Women of childbearing potential must agree not to donate eggs from screening visit and continuously until 90 days after receiving the last immunization
• Men must agree to practice a highly effective form of contraception with their female partner of childbearing potential from screening visit and continuously until 90 days after receiving the last immunization
• Men must be willing to refrain from sperm donation, from screening visit and continuously until 90 days after receiving the last immunization
• All participants must agree not to be vaccinated with any vaccine other than the study vaccine during the study, starting after screening visit and continuously until 28 days after receiving the last immunization

You may not qualify if:

• Any acute illness, with or without fever within 72 hours prior to the first immunization
• Pregnancy, lactation, or intention to become pregnant during the study
• Have a known allergy, hypersensitivity, or intolerance to the planned Investigational Medicinal Product (IMP), adjuvants, and including any excipients of the IMP
• Have any medical condition or any major surgery within the past 5 years which could compromise their well-being if they participate in the study, or that could prevent, limit, or confound the protocol-specified assessments
• Have any surgery planned during the study, starting after screening and continuously until at least 90 days after receiving the last immunization
• Any confirmed or suspected immunosuppressive or immunodeficient state and chronic immunosuppressant medication within the past 6 months
• Received any live or inactivated vaccination within 6 months prior to screening or other vaccinations within the 28 days prior to screening
• Have a history of hypersensitivity or serious reactions to previous vaccinations or a history of Guillain-Barré Syndrome within 6 weeks following a previous vaccination
• Had administration of any immunoglobulins and/or any blood products within the 3 months prior to screening
• Had administration of another IMP including vaccines within 90 days or 5 half-lives prior to screening (Visit 1)
• Hepatitis B surface antigen detected in serum at screening
• Seropositive for hepatitis C virus at screening
• Have a history of or suspected immunosuppressive condition, acquired or congenital
• Symptoms of COVID-19 within 30 days prior to screening
• Alcohol or substance abuse that might interfere with the study conduct or completion

Sponsors & Collaborators

• SpyBiotech Limited: lead

Study Sites (2)

Velocity Bristol

Bristol, United Kingdom

Location

Medicines Evaluation Unit

Manchester, United Kingdom

Location

MeSH Terms

Conditions

Cytomegalovirus Infections

Condition Hierarchy (Ancestors)

Herpesviridae Infections; DNA Virus Infections; Virus Diseases; Infections

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2023
• First Posted: November 24, 2023
• Study Start: November 22, 2023
• Primary Completion: June 20, 2025
• Study Completion: July 9, 2025
• Last Updated: September 22, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

GB (2)